Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(3.42)
# 902
Out of 4,898 analysts
131
Total ratings
45.3%
Success rate
4.83%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Initiates: Overweight | $25 | $7.01 | +256.63% | 1 | Jul 1, 2025 | |
| CMPS COMPASS Pathways | Downgrades: In-Line | $11 → $6 | $3.71 | +61.73% | 2 | Jun 23, 2025 | |
| SEPN Septerna | Maintains: Overweight | $20 → $25 | $12.01 | +108.16% | 3 | May 16, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $20 → $30 | $3.05 | +883.61% | 5 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $174.89 | +60.11% | 4 | May 2, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $25.90 | +189.58% | 4 | Apr 28, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $11.75 | +325.53% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $2.18 | +817.43% | 2 | Mar 25, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $47.69 | +99.20% | 11 | Feb 21, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $150.41 | +42.94% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.64 | +89.39% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $26.18 | +663.94% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $19.02 | +31.44% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.30 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $17.90 | +67.60% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.38 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.67 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $33.01 | +172.64% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.47 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $101.89 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.61 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.31 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.61 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $69.91 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.42 | +3,471.43% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $33.57 | +57.88% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $32.61 | +99.33% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $53.28 | +12.61% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.69 | +2,858.58% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.81 | +77.94% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.46 | +653.42% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $135.12 | -3.79% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $570.59 | +33.20% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $13.35 | +12.36% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $7.86 | +599.75% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.29 | +1,210.04% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.15 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.70 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $318.86 | -21.60% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $70.00 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $42.55 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.43 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $14.70 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $14.55 | +51.20% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.46 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $58.23 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $191.52 | -50.40% | 1 | Aug 17, 2017 |
Trevi Therapeutics
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $7.01
Upside: +256.63%
COMPASS Pathways
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $3.71
Upside: +61.73%
Septerna
May 16, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $12.01
Upside: +108.16%
Rocket Pharmaceuticals
May 16, 2025
Maintains: Overweight
Price Target: $20 → $30
Current: $3.05
Upside: +883.61%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $174.89
Upside: +60.11%
CG Oncology
Apr 28, 2025
Reiterates: Overweight
Price Target: $75
Current: $25.90
Upside: +189.58%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $11.75
Upside: +325.53%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $2.18
Upside: +817.43%
BridgeBio Pharma
Feb 21, 2025
Reiterates: Overweight
Price Target: $95
Current: $47.69
Upside: +99.20%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $150.41
Upside: +42.94%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.64
Upside: +89.39%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $26.18
Upside: +663.94%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $19.02
Upside: +31.44%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.30
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $17.90
Upside: +67.60%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.38
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.67
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $33.01
Upside: +172.64%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.47
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $101.89
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.61
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.31
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.61
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $69.91
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.42
Upside: +3,471.43%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $33.57
Upside: +57.88%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $32.61
Upside: +99.33%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $53.28
Upside: +12.61%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.69
Upside: +2,858.58%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.81
Upside: +77.94%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.46
Upside: +653.42%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $135.12
Upside: -3.79%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $570.59
Upside: +33.20%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $13.35
Upside: +12.36%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $7.86
Upside: +599.75%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $2.29
Upside: +1,210.04%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.15
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.70
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $318.86
Upside: -21.60%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $70.00
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $42.55
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.43
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $14.70
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $14.55
Upside: +51.20%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $11.46
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $58.23
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $191.52
Upside: -50.40%